Product Images Tegsedi

This seems to be a chart or table showing the percentage of patients who had a change in their quality of life related to neuropathic pain in Norfolk. The table presents different categories of change, including "better" and "worse", and the number of patients in each category. However, without additional context it is difficult to understand the significance of these findings.*

This is a description of a medical device that likely involves the use of a plunger, finger grip, and needle. There is an expiration date provided on the body of the device. The text also suggests that the device has a safety feature that automatically retracts the needle after use. However, part of the text is not available due to errors.*

This text is a set of instructions that guide someone on how to use a plunger. It advises them to hold the plunger fully down and wait for five seconds.*

Tegsedi is a medication available in injection form. It contains 284 milligrams per 1.5 milliliters or equivalent to 300 milligrams of inotersen sodium. It is intended for subcutaneous use and is manufactured by Akcea Therapeutics, Inc. The product has an expiry date indicated as MMM YYYY and a lot number identified as (01)00372126007028.*

This is a product packaging for Tegsedi, an injection used for subcutaneous use. It contains 284 mg of inotersen, equivalent to 300 mg of inotersen sodium in a 1.5 mL of sterile solution. The product should not be frozen and must be protected from light. It is distributed by Sobi, Inc. located in Waltham, MA 02451.*

Tegsedi® L is a sterile solution for subcutaneous injection containing 284 mg of inotersen per 1.5 mL prefilled syringe. The solution should be stored refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light. The solution can be stored at room temperature up to 30°C (86°F) for up to six weeks after dispensing. The package contains four prefilled syringes. The inactive ingredients in the solution include sodium hydroxide, hydrochloric acid, and water for injection. The prescribing information and instructions for use should be followed for dosage and administration.*